3-year rolling work plan for the Quality Innovation Group (QIG) 2026-2028
Submitted by Anonymous (not verified) on 15 January 2026 - 12:16
3-year rolling work plan for the Quality Innovation Group (QIG) 2026-2028
Medicine evaluation figures
Submitted by Anonymous (not verified) on 15 January 2026 - 12:00
Medicine evaluation figures
Human medicines in 2025
Submitted by Anonymous (not verified) on 15 January 2026 - 8:33
Human medicines in 2025
European Medicines Agency post-authorisation procedural advice for users of the centralised procedure
Submitted by Anonymous (not verified) on 15 January 2026 - 7:57
European Medicines Agency post-authorisation procedural advice for users of the centralised procedure
European Medicines Agency post-authorisation procedural advice for users of the centralised procedure: document with tracked changes
Submitted by Anonymous (not verified) on 15 January 2026 - 7:56
European Medicines Agency post-authorisation procedural advice for users of the centralised procedure: document with tracked changes
PSUSA/00000851/202503
Submitted by Anonymous (not verified) on 14 January 2026 - 15:30
PSUSA/00000851/202503
Human medicines European public assessment report (EPAR): Roctavian, valoctocogene roxaparvovec, Date of authorisation: 24/08/2022, Revision: 10, Status: Authorised
Submitted by Anonymous (not verified) on 14 January 2026 - 15:28
Human medicines European public assessment report (EPAR): Roctavian, valoctocogene roxaparvovec, Date of authorisation: 24/08/2022, Revision: 10, Status: Authorised
EMA and FDA set common principles for AI in medicine development
Submitted by Anonymous (not verified) on 14 January 2026 - 15:18
EMA and FDA set common principles for AI in medicine development
Guiding principles of good AI practice in drug development
Submitted by Anonymous (not verified) on 14 January 2026 - 14:56
Guiding principles of good AI practice in drug development
Human medicines European public assessment report (EPAR): Zvogra, denosumab, Date of authorisation: 17/11/2025, Revision: 1, Status: Authorised
Submitted by Anonymous (not verified) on 14 January 2026 - 14:36
Human medicines European public assessment report (EPAR): Zvogra, denosumab, Date of authorisation: 17/11/2025, Revision: 1, Status: Authorised